Q-omics provides the consensus-scored MAFG-DT profile across patient tissues and cancer cell-line models. MAFG-DT expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MAFG-DT is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, MAFG-DT RNA expression shows 17,846 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, COAD, and LSCC as cancer lineages where MAFG-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAFG-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAFG-DT survival associations across molecular data types. MAFG-DT RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAFG-DT RNA expression–survival associations across cancer types. High MAFG-DT expression shows unfavorable associations in BLCA, KIRC, ACC, LIHC and SARC, but favorable associations in HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for MAFG-DT RNA expression.
This table summarizes MAFG-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MAFG-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAFG-DT shows lower tumor expression in KIRC and KICH and higher tumor expression in COAD, BLCA, LUAD and LIHC. The COAD box plot shows higher MAFG-DT RNA expression in tumor versus normal tissue (log2 FC = +2.739, t-test p < 0.001).
This table shows molecular features associated with MAFG-DT in patient tissues and cancer cell lines. In patient samples, MAFG-DT shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
